Agenda
09.00 – 09.30
Opening statements
09.30 – 09.45
Introduction to the program
09.45 – 10.30
Evolution in the diagnostic of rare genetic epilepsies
Moderator: Stephan Auvin, INSERM France
When Before genetics: clinical diagnosis of rare epilepsies
Rocío Sánchez Carpintero, Clínica Universidad de Navarra
The genetic revolution in rare epilepsies
Sara Álvarez, NIMGenetics
10.30 – 11.00
Coffee break
11.00 – 12.30
Treating seizures: symptomatic treatment of Dravet syndrome
Moderator: Antonio Gil-Nagel, Hospital Ruber Internacional
Treatment decisions in pharmacoresistant epilepsy patients
Antonio Gil-Nagel, Hospital Ruber Internacional
The development of Epidiolex
Ángel Aledo, Hospital Ruber Internacional
The development of Fintepla
Stephan Auvin, INSERM France
The development of OV935
Rocío Sánchez-Carpintero, Clínica Universidad de Navarra
12.30 – 13.30
Lunch break
13.30 – 15.10
Treating genes: disease-modifying treatment of Dravet syndrome
Moderator: Rubén Hernández, Cima Universidad de Navarra
Targeting Nav1.1-interneurons to restore cognitive and network functions
Jorge Palop, Gladstone Institutes
Gene therapy approaches for Dravet Syndrome
Rajvinder Karda, University College of London
Delivery of the entire SCN1A coding sequence using High-Capacity Adenoviral vectors for the treatment of Dravet Syndrome
Ana Ricobaraza, Cima Universidad de Navarra
Restoring gene expression with gene therapy
tbc
TANGO technology and its application to Dravet Syndrome: a novel approach to the cause of the disease
Javier Avendaño, Stoke Therapeutics
15.10 – 15.30
Coffee Break
15.30 – 15.50
Patient organizations as partners in drug development
15.50 – 16.30
Open discussions and closure
Con el aval científico de la Sociedad Española de Neurología
With the scientific endorsement of the Spanish Society of Neurology